HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

Summary

This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed. The study will be performed only on two sites

Timeline

Start

2020-06-23

Primary completion

2022-07-14

Completion

2022-10-01

Drugs

Indications